Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | PRKCI | P41743 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | GRM6 | O15303 | 1/20 | 0.61 |
| ▸ | MPI | P34949 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690278 | 0.89 | PRKCZ (0.84) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL8289654 | 0.89 | PRKCZ (1.00) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL1554182 | 0.88 | PRKCZ (0.82) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL8290363 | 0.88 | PRKCZ (0.82) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL8288644 | 0.87 | PRKCZ (0.77) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL689112 | 0.86 | PRKCZ (0.80) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL690269 | 0.86 | PRKCZ (1.00) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL689452 | 0.86 | PRKCZ (0.80) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL1190649 | 0.86 | PRKCZ (0.80) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL8290362 | 0.86 | PRKCZ (0.75) | PRKCZALDH1A1HSD17B10HPGDPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619968-A | Dihydrothienopyrimidino pyrido indol-4-one derivative and application thereof | 新疆工程学院 | 2024-09-10 | — | — | CN | disclosed |
| EP-2744812-B1 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-07-20 | — | — | EP | disclosed |
| US-9227984-B2 | Therapeutically active fused pyrimidine derivatives | UCB PHARMA S.A. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-8889672-B2 | Compounds, formulations, and methods of protein kinase C inhibition | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889672-B2 | Compounds, formulations, and methods of protein kinase C inhibition | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-10-16 | — | — | US | disclosed |
| EP-2744812-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013024291-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-02-21 | — | — | WO | disclosed |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-20080076926-A1 | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles | WYETH | 2008-03-27 | — | — | US | disclosed |
| EP-1879899-A1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060183759-A1 | Tissue transglutaminase inhibitors | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2006-08-17 | — | — | US | disclosed |
| US-20060183768-A1 | Compounds | XENTION DISCOVERY LTD. (GB) | 2006-08-17 | — | — | US | disclosed |
| WO-2006061642-A1 | COMPOUNDS | XENTION DISCOVERY LIMITED (GB) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006060702-A1 | SUBSTITUED 3,4-DIHYDROTHIENO [2,3-D] PYRMIDINES AS TISSUE TRANSGLUTAMINASE INHIBITORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| EP-1641803-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005033102-A2 | THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050026935-A1 | Compounds | XENTION DISCOVERY LTD. | 2005-02-03 | — | — | US | disclosed |
| WO-2004111057-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183768-A1 | Compounds | SCN7A, CBR3, SCN8A | PRKCZ 3193/4885ALDH1A1 2799/4885HSD17B10 850/4885 |
| US-20080076926-A1 | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles | MAP4K2, MAP4K1, MAP4K3 | PRKCZ 242/4885ALDH1A1 3947/4885HSD17B10 1689/4885 |
| US-20050026935-A1 | Compounds | KCNJ11, KCNJ1, KCNH1 | PRKCZ 2857/4885ALDH1A1 247/4885HSD17B10 905/4885 |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | HAVCR2, TPMT, PAICS | PRKCZ 2221/4885ALDH1A1 1119/4885HSD17B10 4202/4885 |
| US-20060183759-A1 | Tissue transglutaminase inhibitors | TGM2, HNMT, TPMT | PRKCZ 3494/4885ALDH1A1 3116/4885HSD17B10 1221/4885 |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | PRKCA, PRKCH, PRKCI | PRKCZ 5/4885ALDH1A1 4665/4885HSD17B10 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.